866-997-4948(US-Canada Toll Free)

Bone Marrow Transplantation - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Jan 2014

Category :

Biotechnology

No. of Pages : 60 Pages


Global Markets Directs, \'Bone Marrow Transplantation Pipeline Review, H1 2014\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Bone Marrow Transplantation Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Bone Marrow Transplantation.
  • A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bone Marrow Transplantation Overview 6
Therapeutics Development 7
Pipeline Products for Bone Marrow Transplantation - Overview 7
Pipeline Products for Bone Marrow Transplantation - Comparative Analysis 8
Bone Marrow Transplantation - Therapeutics under Development by Companies 9
Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes 10
Bone Marrow Transplantation - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bone Marrow Transplantation - Products under Development by Companies 14
Bone Marrow Transplantation - Products under Investigation by Universities/Institutes 15
Bone Marrow Transplantation - Companies Involved in Therapeutics Development 16
Mesoblast Limited 16
Cleveland BioLabs, Inc. 17
Pluristem Therapeutics Inc. 18
Spectrum Pharmaceuticals, Inc. 19
TikoMed AB 20
Bone Marrow Transplantation - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Assessment by Therapeutic Class 30
Drug Profiles 32
Allogeneic MPC For Bone Marrow Transplantation - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
melphalan - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TM-400 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
PLX-BMP - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CBLB-612 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CBLB-612 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Perforin Inhibitor - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Bone Marrow Transplantation - Recent Pipeline Updates 44
Bone Marrow Transplantation - Dormant Projects 48
Bone Marrow Transplantation - Discontinued Products 49
Bone Marrow Transplantation - Product Development Milestones 50
Featured News & Press Releases 50
Nov 13, 2013: Improved Survival In Children With Life Threatening Graft Versus Host Disease Reported After Treatment With Mesoblast\'s Cell Therapy 50
Nov 04, 2013: Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients 51
Oct 29, 2013: Pharmalink Receives US Orphan Drug Designation for Busulipo, its Novel Oncology Product for Bone Marrow Transplantation 51
Sep 03, 2013: BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells 52
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 53
Dec 05, 2012: URMC Researchers Test New Approach To Accelerate Blood Stem Cells 54
Nov 06, 2012: Cleveland BioLabs Announces Publication Of Studies On Effect Of Entolimod On Graft-versus-tumor Activity In Models Of Allogeneic Bone Marrow Transplantation 55
Oct 24, 2012: Enlivex Therapeutics Completes Clinical Trial For Treatment Of Bone Marrow Transplant Recipients, Reports Positive Results 55
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 56
Aug 06, 2012: Pluristem\'s PLX Cells Save Life Of Cancer Patient Suffering From Bone Marrow Failure 57

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products under Development for Bone Marrow Transplantation, H1 2014 7
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Number of Products under Investigation by Universities/Institutes, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Bone Marrow Transplantation - Pipeline by Mesoblast Limited, H1 2014 16
Bone Marrow Transplantation - Pipeline by Cleveland BioLabs, Inc., H1 2014 17
Bone Marrow Transplantation - Pipeline by Pluristem Therapeutics Inc., H1 2014 18
Bone Marrow Transplantation - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 19
Bone Marrow Transplantation - Pipeline by TikoMed AB, H1 2014 20
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Stage and Target, H1 2014 23
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Number of Products by Stage and Therapeutic Class, H1 2014 31
Bone Marrow Transplantation Therapeutics - Recent Pipeline Updates, H1 2014 44
Bone Marrow Transplantation - Dormant Projects, H1 2014 48
Bone Marrow Transplantation - Discontinued Products, H1 2014 49

List of Chart


Number of Products under Development for Bone Marrow Transplantation, H1 2014 7
Number of Products under Development for Bone Marrow Transplantation - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 21
Number of Products by Top 10 Target, H1 2014 22
Number of Products by Stage and Top 10 Target, H1 2014 23
Number of Products by Top 10 Mechanism of Action, H1 2014 24
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 25
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29
Number of Products by Top 10 Therapeutic Class, H1 2014 30
Number of Products by Stage and Top 10 Therapeutic Class, H1 2014 31

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *